Life science healthcare executive with global experience in biotechnology and technology. Meldrum is currently CEO of AdhereTech, a HealthTech company focused on improving medication adherence in clinical trials and real-world settings. Previously, he served as CEO of Reset Pharma, developing psychedelics for mental health disorders, and as Chief Commercial Officer for Otsuka Pharmaceuticals North America, where he delivered revenue growth despite pandemic challenges.

His career includes commercial leadership at Orexo, where he developed the award-winning "Out The Monster" campaign, and 11 years at Novartis Pharma in the US and Switzerland. Before healthcare, Meldrum spent 10 years in technology, building on his Electrical and Electronic degree from Strathclyde University.

Meldrum brings extensive expertise in psychiatry, neuroscience, respiratory, dermatology, and digital health, with demonstrated success across organizations of all sizes. Outside work, he's a certified scotch professional and enthusiastic golfer.

Steven M Ferguson currently serves as Special Advisor at the NIH Office of Technology Transfer where he has worked since 1990.  The biomedical technology transfer program at NIH is one of the world’s largest with a portfolio that includes over 2,000 active licenses with aggregate sales greater than $10B per year that is based upon research that has also generated 48 FDA-approved drugs & vaccines. 

A former chemist at the National Cancer Institute and biotech industry product manager, Mr Ferguson holds Master's Degrees in Business Administration (George Washington University) and Chemistry (University of Cincinnati) as well as Bachelor’s Degree in Chemistry (Case Western Reserve University).   

A registered Patent Agent and a Certified Licensing Professional (CLP), Mr Ferguson has served as faculty and Technology Transfer Department Chair at the Foundation for Advanced Education in the Sciences (FAES) Graduate School at NIH and the Biotechnology Industry Organization “BIO Boot Camp”.  He also serves as a business reviewer or advisory board member for the US-India Science & Technology Endowment Fund, Maryland Industrial Partnerships, Maryland Innovation Initiative, Virginia Bio-Life Science Gap Fund, US Department of Education Small Business Innovative Research (SBIR) program, the Journal of Commercial Biotechnology and the DOD Congressionally Directed Medical Research Program.

He has published extensively in the field of technology transfer and has also received the AUTM President’s Award (AUTM Band), the AUTM Volunteer Service Award, the NIH Director’s Award, the FAES Instruction Award, five “Deal of Distinction” awards and the Frank Barnes Mentoring Award from the Licensing Executive Society, six Federal Laboratory Consortium Awards, and twenty NIH Merit Awards in recognition of his service and activities in technology transfer.

Kara Prosser is a Director at consulting firm Baringa, where her team deliver end to end transformation through patient experience & process simplification. Kara is an Experience Designer by background, and deeply passionate about tackling society’s biggest health challenges through design & innovation. She’s spent the last 15 years working with start-ups, NFP’s, governments & corporates delivering initiatives that improve people’s lives. She’s worked in over 45 countries with some of the world’s biggest companies to eradicate malaria, transform mental health, & reimagine clinical trials.

I am the Country Head of SMO Pratia Ukraine and Director of Pratia Clinic Ukraine, the first SMO clinical research site on the territory of Ukraine. I am a qualified cardio rheumatologist, Ph.D., Professor at Medical Academy, MBA, and a certified international lecturer. I have finished training courses at Harvard and Yale Universities in Finance and Management. Furthermore, I am an author of more than 100 scientific publications, and I have five patents for medical inventions. I am a member of a Scientific Board in the International Medical Journal.

As the Country Head of SMO Pratia Ukraine and Director of Pratia Clinic Ukraine, I lead the network of 8 embedded research sites in the country and created the first SMO clinical research site on the territory of Ukraine. A qualified cardio rheumatologist, PhD, MBA, Professor Assoc., and MSc in International Education, I bring diverse expertise to the field. Since 2022, I have also taken on the role of International Operations Director at Pratia, overseeing the global aspects of clinical trial operations. Having completed training courses at Harvard and Yale Universities in Finance and Management, I continue to expand my skill set. With more than 100 scientific publications and five patents for medical inventions to my name, I contribute actively to advancing the medical field. As a member of the Scientific Board of the International Medical Journal and several esteemed organizations, including DTRA, SCRS, AACR, and the Institute for Human Centered Health Innovation in Switzerland, I engage with global research communities.

As a value-driven healthcare leader, I excel in guiding diverse teams and driving business and medical innovation. With a strong background in medical affairs, international clinical operations, strategic planning, and financial management, I am committed to shaping the future of clinical research through expertise and leadership, following Steve Jobs’s famous quote: ‘The only way to do great job is to love what you do.

Heather Manley brings over 12 years of experience in clinical research, specializing in phase II–IV sponsor trials, investigator-initiated studies, and CRO capacities. Her expertise spans site operations, monitoring, data management, and statistical analysis. She has worked extensively in therapeutic areas including migraine, chronic pain, metabolic disorders, cardiovascular disease, and rheumatic conditions.

Heather holds a Master of Science in Psychology with a graduate certificate in Statistics and Research Design. She joined Clinvest over a decade ago, initially supporting CRO activities for investigator-initiated trials. For the past 10+ years, she has served as Site Director, where she leads clinical trial operations, ensures adherence to high-quality standards, and collaborates closely with sponsors, CROs, and key stakeholders to drive trial success from initiation through closeout.

Since Clinvest became part of the Headlands Research network in 2023, Heather has continued to lead the site while contributing to broader network initiatives and strategic committees. Her deep operational knowledge and leadership experience position her as a valuable resource to both Clinvest Headlands and its research partners.

Emily Goldsher-Diamond is a leader in ZS’s R&D practice and a founding member of ZS’s Site and Patient Engagement and Recruitment team. She brings nearly a decade of experience applying human-centered design to help life sciences companies embed patient and site perspectives into clinical trials and broader organizational strategies. Trained as a medical anthropologist, she is especially focused on how cultural and structural dynamics shape trial execution in the real world. Her expertise in qualitative research, co-design, and ethnography has informed trial design and engagement strategies across 25+ countries, helping sponsors build more inclusive and effective trials.

Christina drives strategic growth and operational excellence with a global perspective.

With over 25 years of operational and management experience leading cross-functional teams at a range of clinically focused companies across North America, Europe, and Asia-Pacific, Christina brings a unique ability to unify diverse groups under a cohesive vision.

Throughout her career, she has empowered healthcare companies to refine strategy, optimize structure, and accelerate growth. Christina’s leadership has been instrumental in navigating complex acquisitions and integrating multinational teams, fostering a culture of collaboration and innovation.

She holds a BS in biology from Yale University and an MBA from The Wharton School. Christina has co-authored five scientific publications and has been recognized as a PharmaVoice 100 winner.

 Mindy Cameron is a long-time advocate for patient-centered research in neuromuscular and rare disease communities. As the President of AdvocacyWorks Consulting, Mindy helps non-profit and industry colleagues develop research and clinical trial initiatives that work for all stakeholders, with a particular focus on the most important participants in clinical research…patients and their caregivers.

She has the personal experience to back up her professional expertise, as she and her son, who lives with Duchenne muscular dystrophy, have participated in nearly a dozen research studies and clinical trials over the past 20 years. Mindy serves as a patient advisor to the Critical Path Institute’s Duchenne Regulatory Science Consortium and is a member of the American Academy of Pediatrics Muscular Dystrophy Public Health Consortium. She is also an active member of the EveryLife Foundation’s regulatory and access working groups, as well as the Rare Disease Advisory Council for the State of Indiana.

She is a frequent speaker on a range of topics relevant to clinical trial design, including patient data return, data sharing, accessibility at clinical trial sites, patient preferences and lived experiences, and post-approval access and reimbursement challenges.

Angela joined the MRC Clinical Trials Unit in December 1999 as a Clinical Trial Manager for the unit’s first multi-arm trial, FOCUS. She worked on a number of colorectal cancer clinical trials, before becoming a Project Lead in 2007. Angela has since led a prison-based trial investigating the use of take-home naloxone (n-ALIVE) as well as a number of international oncology trials.

Angela is currently responsible for leading the international RAMPART trial in kidney cancer and co-leads the large Add-Aspirin trial in four tumour cohorts (breast, colorectal, gastro-oesophageal and prostate cancer). 

Angela is the Director of Education at the Institute of Clinical Trials and Methodology (ICTM), responsible for the department's postgraduate and undergraduate taught programmes / modules.  Angela developed the institute's first postgraduate taught programme in 2015.

Angela has a PhD from the University of Ulster and an MSc in Clinical Trials from the London School of Hygiene and Tropical Medicine (LSHTM). She is a Senior Fellow of the Higher Education Academy.

Dr. Bernhard Glombitza is a distinguished leader in the healthcare industry, currently serving as Head of Clinical Customer Engagement and Operations for EMEA & LATAM at Bayer. His career journey began with project leadership roles, notably spearheading the global Xarelto project team, which contributed significantly to its market success. In Clinical Operations, he has managed organizations with over 1000 individuals across more than 40 countries, achieving a 25% increase in productivity through strategic organizational restructuring and innovative resource management. Dr. Glombitza is currently leading the implementation of the Dynamic Shared Ownership model (DSO), decentralizing decision-making and optimizing talent allocation to drive impactful results, all while fostering an environment of psychological safety and appreciation.

TBA

Siân is currently SVP, Head of Quantitative Sciences & Development Operations (QSDO) at Biogen, where she leads a global team accountable for the strategic planning, execution and analysis of clinical trials across all phases of development and therapeutic areas, ie MS/Immunology, Rare Disease (Neuromuscular Disorders, Genetic Neurodevelopmental Disorders) and Neuroscience (Alzheimer’s Disease, Movement Disorders, Psychiatry). Siân and her team are driving numerous innovation projects to transform clinical trials and accelerate clinical development. Prior to Biogen, Siân spent 20+ years Pfizer, where she held senior leadership and group head roles in Clinical Operations, Medical Writing, Clinical Development, Preclinical Safety (Toxicology and Safety Pharmacology), Safety Risk Management and Regulatory Strategy, managing projects throughout development stages from research to post-approval in multiple therapeutic areas (including Oncology, Neurology, Psychiatry, Pain, Rare Disease, Immunology, Internal Medicine, Women’s Health and Vaccines). In addition, Siân has co-led a number of cross-industry initiatives for TransCelerate, BIO, ICH and public-private partnerships to advance clinical trial innovation approaches, precision medicine drug development and translational sciences. Siân has a PhD in Pharmacology from the University of Cambridge where she also held post-doctoral research and academic posts. Siân also serves on the Executive Committee as Treasurer for the International Society for CNS Clinical Trials Methodology (ISCTM), co-leads the ISCTM CNS Clinical Trial Diversity Working Group and mentors new investigators involved in psychiatry and neurology research.